O-RADS MRI System on Early Detection of Ovarian Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

2,549

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Ovarian Cancer (OvCa)Ovarian Cancer Metastatic
Interventions
DIAGNOSTIC_TEST

MRI contrast-enhancing agents

All patients underwent standard pelvic MRI examinations (1.5T or 3T) with the following sequences: T2-weighted imaging (T2WI), T1-weighted imaging (T1WI) with and without fat suppression; axial, sagittal, and coronal post-contrast T1WI following intravenous administration of gadolinium-based contrast agents (GBCA); functional sequences including dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging MRI (DWI-MRI). Enhancement sequences may be omitted if no adnexal masses were identified on T2WI, T1WI, or DWI sequences.

Trial Locations (1)

200032

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Gynecologic Oncology Group

OTHER_GOV